Endpoints News
Cayman court rules against Apple Tree general partner Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
13 July, 2026
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
top stories
1. FDA finalizes guidance on psychedelics, plans broader hearing
2. Cayman court says Apple Tree general partner should lose control of venture fund 
3. FDA proposes to streamline registration of drugmakers' foreign and US factories
4. Biopharma's 'extraordinary year' for M&A sets tone as earnings cycle begins
5.
news briefing
Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
more stories
 
Lydia Ramsey Pflanzer
.

I spent the day at the American Hospital Association Leadership Summit happening in Denver. 340B, of course, has been a hot topic — as has what's changing within health systems as they integrate more AI.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Max Bayer

The FDA has fi­nal­ized clin­i­cal guid­ance for psy­che­del­ic drug de­vel­op­ers and has sched­uled a pub­lic hear­ing on fu­ture ther­a­peu­tic use, adding reg­u­la­to­ry mo­men­tum to a...

Read the full story
2
by Nicole DeFeudis

The em­bat­tled ven­ture firm Ap­ple Tree Part­ners has suf­fered a loss in a Cay­man Is­lands court case against its main lim­it­ed part­ner.

A judge in...

Read the full story
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
3
by Anna Brown

The FDA is propos­ing a rule to change how fac­to­ries are reg­is­tered with the agency if they are mak­ing prod­ucts for the US mar­ket, as...

Read the full story
4
by Max Gelman

With the first half of 2026 of­fi­cial­ly in the books and an­oth­er earn­ings sea­son about to be­gin, a key ques­tion hangs over the bio­phar­ma in­dus­try...

Read the full story
News Briefing: Quick hits from the biopharma web
5
by ENDPOINTS

Plus, news about In­sil­i­co, Ipsen, Q32 Bio, GSK’s Jem­per­li, Drug Farm and Pad­cev.

❌ FDA re­jects Tris Phar­ma’s nar­colep­sy drug: Its re­jec­tion let­tersaid that...

Read the full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.